{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:24:09Z","timestamp":1792657449330,"version":"4.5.0"},"reference-count":33,"publisher":"Japan Endocrine Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2015]]},"DOI":"10.1507\/endocrj.ej15-0401","type":"journal-article","created":{"date-parts":[[2015,10,16]],"date-time":"2015-10-16T18:00:40Z","timestamp":1445018440000},"page":"1101-1114","source":"Crossref","is-referenced-by-count":27,"title":["A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial"],"prefix":"10.1507","volume":"62","author":[{"given":"Masanori","family":"Emoto","sequence":"first","affiliation":[{"name":"Department of Metabolism, Endocrinology & Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, 545-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Terauchi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology & Metabolism, Yokohama City University School of Medicine, Yokohama, 236-0004, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akichika","family":"Ozeki","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K., Kobe, 651-0086, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Oura","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K., Kobe, 651-0086, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K., Kobe, 651-0086, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Imaoka","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K., Kobe, 651-0086, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, et al. (2002) The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. <i>Diabetes<\/i> 51 Suppl 3:S434-S442.","DOI":"10.2337\/diabetes.51.2007.S434"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Gutzwiller JP, Degen L, Heuss L, Beglinger C (2004) Glucagon-like peptide 1 (GLP-1) and eating. <i>Physiol Behav<\/i> 82:17-19.","DOI":"10.1016\/j.physbeh.2004.04.019"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Mudaliar S, Henry RR (2009) Incretin therapies: effects beyond glycemic control. <i>Am J Med<\/i> 122:S25-S36.","DOI":"10.1016\/j.amjmed.2009.03.014"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, et al. (2011) An overview of once-weekly glucagon-like peptide-1 receptor agonists&mdash;available efficacy and safety data and perspectives for the future. <i>Diabetes Obes Metab<\/i> 13:394-407.","DOI":"10.1111\/j.1463-1326.2011.01357.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Lorenz M, Evers A, Wagner M (2013) Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. <i>Bioorg Med Chem Lett<\/i> 23:4011-4018.","DOI":"10.1016\/j.bmcl.2013.05.022"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Lund A, Knop FK, Vilsb&oslash;ll T (2014) Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. <i>Eur J Intern Med<\/i> 25:407-414.","DOI":"10.1016\/j.ejim.2014.03.005"},{"key":"7","unstructured":"7. Victoza [Japan package insert]. Tokyo Japan: Novo Nordisk Pharma Ltd 2014. Available from http:\/\/www.info.pmda.go.jp\/downfiles\/ph\/PDF\/620023_2499410G1021_1_08.pdf (In Japanese). Accessed 16 June 2015."},{"key":"8","unstructured":"8. Byetta [Japan package insert], Osaka Japan: AstraZeneca K.K.2015. Available from http:\/\/www.info.pmda.go.jp\/downfiles\/ph\/PDF\/670227_2499411G1026_2_04.pdf (In Japanese). Accessed 16 June 2015."},{"key":"9","unstructured":"9. Bydureon [Japan package insert]. Osaka Japan: AstraZeneca K.K. 2015. Available from http:\/\/www.info.pmda.go.jp\/downfiles\/ph\/PDF\/670227_2499411G3029_1_11.pdf (In Japanese). Accessed 16 June 2015."},{"key":"10","unstructured":"10. Lyxumia [Japan package insert]. Tokyo Japan: Sanofi K.K. 2014. Available from http:\/\/www.info.pmda.go.jp\/downfiles\/ph\/PDF\/780069_2499415G1024_1_04.pdf (In Japanese). Accessed 16 June 2015."},{"key":"11","unstructured":"11. Trulicity [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC 2014. Available from http:\/\/pi.lilly.com\/us\/trulicity-uspi.pdf Accessed 16 June 2015."},{"key":"12","unstructured":"12. Trulicity [Summary of Product Characteristics]. Houten, The Netherlands: Eli Lilly and Company 2015. Available from http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002825\/WC500179470.pdf Accessed 24 September 2015."},{"key":"13","unstructured":"13. Trulicity Ateos [Japan package insert]. Hyogo Japan: Eli Lilly Japan K.K. 2015. Available from http:\/\/www.info.pmda.go.jp\/downfiles\/ph\/PDF\/530471_2499416G1029_1_03.pdf (In Japanese). Accessed 24 September 2015."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Glaesner W, Vick AM, Millican R, Ellis B, Tschang SH, et al. (2010) Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. <i>Diabetes Metab Res Rev<\/i> 26:287-296.","DOI":"10.1002\/dmrr.1080"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Umpierrez G, Tof&eacute; Povedano S, P&eacute;rez Manghi F, Shurzinske L, Pechtner V (2014) Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). <i>Diabetes Care<\/i> 37:2168-2176.","DOI":"10.2337\/dc13-2759"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, et al. (2014) Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). <i>Diabetes Care<\/i> 37:2149-2158.","DOI":"10.2337\/dc13-2761"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V (2015) Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). <i>Diabetes Care<\/i> 38:2241-2249.","DOI":"10.2337\/dc14-1625"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, et al. (2014) Efficacy and safety of dulaglutide added on to pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). <i>Diabetes Care<\/i> 37:2159-2167.","DOI":"10.2337\/dc13-2760"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Dungan KM, Povedano ST, Forst T, Gonzalez JG, Atisso C, et al. (2014) Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. <i>Lancet<\/i> 384:1349-1357.","DOI":"10.1016\/S0140-6736(14)60976-4"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Miyagawa J, Odawara M, Takamura T, Iwamoto N, Takita Y, et al. (2015) Once weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. <i>Diabetes Obes Metab<\/i> 17:974-983.","DOI":"10.1111\/dom.12534"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Araki E, Inagaki N, Tanizawa Y, Oura T, Takeuchi M, et al. (2015) Efficacy and safety of once weekly dulaglutide in combination with sulphonylurea and\/or biguanide compared with once daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. <i>Diabetes Obes Metab <\/i>17:994-1002.","DOI":"10.1111\/dom.12540"},{"key":"22","unstructured":"22. Ministry of Health, Labour and Welfare (2010) On release of the Guideline for Clinical Evaluation of Oral Hypoglycemic Agents. Available from https:\/\/www.pmda.go.jp\/files\/000208194.pdf Accessed 16 June 2015."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Workgroup on Hypoglycemia, American Diabetes Association (2005) Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. <i>Diabetes Care<\/i> 28:1245-1249.","DOI":"10.2337\/diacare.28.5.1245"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. <i>Diabetes Care<\/i> 27:1487-1495.","DOI":"10.2337\/diacare.27.6.1487"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Seino Y, Rasmussen MF, Nishida T, Kaku K (2010) Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. <i>Curr Med Res Opin<\/i> 26:1013-1022.","DOI":"10.1185\/03007991003672551"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Kadowaki T, Namba M, Imaoka T, Yamamura A, Goto W, et al. (2011) Improved glycemic control and reduced bodyweight with exenatide: a double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. <i>J Diabetes Investig<\/i> 2:210-217.","DOI":"10.1111\/j.2040-1124.2010.00084.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Ji L, Onishi Y, Ahn CW, Agarwal P, Chou CW, et al. (2013) Efficacy and safety of exenatide once weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. <i>J Diabetes Investig<\/i> 4:53-61.","DOI":"10.1111\/j.2040-1124.2012.00238.x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Inagaki N, Atsumi Y, Oura T, Saito H, Imaoka T (2012) Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. <i>Clin Ther<\/i> 34:1892-1908.","DOI":"10.1016\/j.clinthera.2012.07.007"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Seino Y, Min KW, Niemoeller E, Takami A; EFC10887 GETGOAL-L Asia Study Investigators (2012) Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). <i>Diabetes Obes Metab<\/i> 14:910-917.","DOI":"10.1111\/j.1463-1326.2012.01618.x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kaku K, Rasmussen MF, Clauson P, Seino Y (2010) Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. <i>Diabetes Obes Metab<\/i> 12:341-347.","DOI":"10.1111\/j.1463-1326.2009.01194.x"},{"key":"31","unstructured":"31. Japan Diabetes Society (2011) Committee on the proper use of incretin drugs (GLP-1 receptor agonists and DPP-4 inhibitors). Available from http:\/\/www.jds.or.jp\/uploads\/photos\/797.pdf (In Japanese). Accessed 16 June 2015."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Pratley RE, Nauck MA, Barnett AH, Feinglos MN, Ovalle F, et al. (2014) Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. <i>Lancet Diabetes Endocrinol<\/i> 2:289-297.","DOI":"10.1016\/S2213-8587(13)70214-6"},{"key":"33","unstructured":"33. Pharmaceuticals and Medical Devices Agency (2014) Review report for new indication of liraglutide (Victoza). http:\/\/www.pmda.go.jp\/drugs\/2014\/P201400122\/620023000_22200AMX00236_A100_1.pdf (In Japanese). Accessed 28 July 2015. <\/p>"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/62\/12\/62_EJ15-0401\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T17:28:53Z","timestamp":1498238933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/62\/12\/62_EJ15-0401\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej15-0401","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}